BACKGROUND It would be useful to identify patients at high risk of implantable cardioverter defibrillator (ICD) therapy via additional antiarrhythmic measures to minimize the morbidity of ICD therapies. OBJECTIVE We assessed baseline characteristics for predictors of device therapy in a general ICD population. We also compared the likelihood of therapy delivery by replacement ICDs implanted f...

Introduction In September 2012, the United Stated Food and Drug Administration approved the use of a fully subcutaneous implantable cardiac defibrillator (S-ICD, Boston Scientific Inc). The device is implanted in the left midaxillary space and attached to a single lead that is tunneled subcutaneously from the xyphoid process in 2 directions, superiorly to the sternal manubrium joint to the left...

BACKGROUND Patient device acceptance might be essential in identifying patients at risk for adverse patient-reported outcomes following implantation of an implantable cardioverter defibrillator (ICD). We examined the validity and reliability of the Florida Patient Acceptance Scale (FPAS) and identified correlates of device acceptance in a Dutch cohort of ICD patients. METHODS Patients with a ...

Ensuring that medical devices, such as pacemakers and implantable cardioverter defibrillators (ICDs), deliver the appropriate therapy only when necessary is made difficult by complex software and variability conditions between patients. Because of patient condition variability, safety recalls have affected over 600,000 devices between 1990 and 2000 [1]. Of these recalled devices, 200,000 were r...

An increasing number of patients have a coexisting implantable cardioverter defibrillator (ICD) and left ventricular assist device (LVAD) to treat ventricular arrhythmias and refractory heart failure, respectively. To date, there have been no published reports of negative interactions between these devices that have impacted appropriate ICD or LVAD function. In this case report, we describe a p...

BACKGROUND Most patients with implantable cardioverter-defibrillator (ICD) implantation fail to utilize the device resulting in increasing societal costs and patient exposure to device morbidity. We sought to determine whether volumetric cardiovascular magnetic resonance (CMR) left ventricular (LV) spherical remodeling predicts future ventricular arrhythmias in primary ICD patients with reduced...

OBJECTIVES This study aimed to assess the prevalence of different types of atrial fibrillation (AF) and their prognostic importance in implantable cardioverter-defibrillator (ICD) patients. BACKGROUND The prevalence of AF has taken epidemic proportions in the population with cardiovascular disease. The prognostic importance of different types of AF in ICD patients remains unclear. METHODS D...

The clinical management of implantable cardioverter-defibrillator (ICD) patients involves successful medical and psychosocial care to reduce mortality and morbidity. Desirable quality of life (QoL) and psychosocial outcomes for ICD patients are achievable for a majority of ICD patients. Patient critical events, such as ICD shocks or ICD recalls, may occur that can dramatically alter the course ...

Case presentation A 60-year-old man presented to our institution’s device clinic for routine evaluation of his ICD. He received his first ICD in 2002 for primary prevention in the setting of ischemic cardiomyopathy. He had had a generator change to a St Jude Medical Fortify Assura VR, model CD1257-40 in September 2012 without any complications. Two months later, he had an interrogation, which s...